Back to top
more

Travere Therapeutics (TVTX)

(Delayed Data from NSDQ)

$58.85 USD

58.85
4,896,262

-0.18 (-0.30%)

Updated Jun 26, 2026 04:00 PM ET

After-Market: $58.86 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:
Message not found:16923

3-Hold of 5     3    

Style Scores:
Message not found:17303

F Value F Growth C Momentum F VGM

Industry Rank:
Message not found:17304

Bottom 37% (154 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Key Expected Earnings Data

Report Date Period Ending Zacks Consensus Estimate Earnings ESP
08/05/2026

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.


Time: -- 		6/2026 $-0.14 135.71%

Earnings Summary

For their last quarter, Travere Therapeutics (TVTX) reported earnings of -$0.39 per share, missing the Zacks Consensus Estimate of -$0.30 per share. This reflects a negative earnings surprise of 30.00%. Look out for TVTX's next earnings release expected on August 05, 2026. For the next earning release, we expect the company to report earnings of -$0.14 per share, reflecting no change in earnings compared to the year-ago quarter.

Earnings History

Research for TVTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

*BMO: Before Market Open

*AMC: After Market Close

Price & Consensus

Zacks News for TVTX

TVTX FAQs

Based on past history, Zacks believes Travere Therapeutics, Inc. (TVTX) will report their next quarter earnings on February 20, 2025. For the next earning release, we expect the company to report earnings of -0.61 per share, reflecting a year-over-year increase of 47.41.

Based on past history, Zacks believes Travere Therapeutics, Inc. (TVTX) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on February 20, 2025.

The Zacks Consensus Estimate for Travere Therapeutics, Inc. (TVTX) for the quarter ending in December 2024 is $-0.61 a share. We expect Travere Therapeutics, Inc. to miss by 9.09%.

In the earnings report for the quarter ending in September 2024, Travere Therapeutics, Inc. (TVTX) announced earnings of $-0.70 per share versus the Zacks Consensus Estimate of $-0.70 per share, representing a surprise of 0.00%.